anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a cell sheet for tissue repair and bio-artificial tissue engineering. The cell sheet comprises treated stem cell embedded in its self-secreted extracellular matrix (ECM) and formed a cell sheet. The cell sheet is formed by isolating the stem cell, expanding the stem cell and treating the stem cell with biological factors or factors leading to the production of biological factors, to induce its differentiation, production of extracellular matrix and formation of a cell sheet in vitro. The cell sheet is used as a bioactive material or as an acellular material for the promotion of tissue repairs or used to form a bio-artificial organ for tissue replacement. The cell sheet of the present invention eliminates the need to use scaffolds for cell delivery. The cell sheet facilitates in vivo cell transplantation and provides some tensile mechanical strength for bearing early mechanical load during tissue repair.
The invention provides novel vectors derived from adenovirus which are specifically suitable for use in methods of gene therapy. <??>The vectors have a deletion compared to wild-type adenovirus in that the E1 region is not present in a functional manner. <??>Additionally the vectors are characterized in that they do contain a part of the E3 region of adenovirus which is biologically functional. This results in vectors which do normally not lead to expression of adenoviral proteins, but which in the cases where such proteins do become expressed will repress the host's immunological response to said proteins. Thereby host cells infected (provided) with the vector will live longer. Therefor the product introduced into said cells providing the therapy will be produced in larger amounts, or at least for a prolonged period. Preferably the vector comprises genetic information for antisense therapy, or for genes which will combat tumors, such as genes encoding cytokines, preferably IL-1, or so called suicide genes, such as Herpes Simplex Virus thymidine kinase. <??>Methods for producing said vectors and methods of gene therapy or uses therein are also disclosed.
NEW MATERIAL:The compound of formulaI[Q is CO or CH(OR); R is H or acyl; X is heterocyclic group of formula II, formula III, etc.; R1 is H or acyl], and its pharmacologically permissible acid addition salt. EXAMPLE:2-{2-[4-(2-Oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)piperidin-1- yl]-oxoethyl}-2,3-dihydro-1,4-benzodioxine. USE:An antihypertension and antiphlogistic agent. It exhibits excellent pharmacological activity, and is useful as a medicine. PROCESS:The compound of e.g. formula VI can be prepared by reacting the compound of formula IV with an optically active novel compound of formula V (Z is halogen or eliminable group) in an inert solvent such as acetone, chloroform, DMF, etc.
A purpose of the present invention is to provide a novel kinase inhibitor and the likes, and to provide a treating agent of diseases using the above inhibitor and a screening method for drug discovery and the likes. The following compound represented by formula (I) or salt thereof comprises LATS (especially LATS2) which is a key kinase of Hippo signal transduction pathway, and can inhibit multiple kinase or can treat diseases or tissue lesions accompanying with cell proliferation deficiency. Therefore, the present invention is useful in the study field of cell functions or disease related with such as Hippo signal transduction pathway. Further, the present invention is useful in the therapeutical field for treating the related diseases. (In formula, all symbols are same as those defined in the present specification.).
###  Elderly

####  Clearance and unbound fraction

The plasma and renal clearance of ketoprofen is reduced in the elderly (mean age, 73 years) compared to a younger normal population (mean age, 27 years). Hence, ketoprofen peak concentration and AUC increase with increasing age. In addition, there is a corresponding increase in unbound fraction with increasing age. Data from one trial suggest that the increase is greater in women than in men. It has not been determined whether age-related changes in absorption among the elderly contribute to the changes in bioavailability of ketoprofen (see Geriatric Use).

In a study conducted with young and elderly men and women, results for subjects older than 75 years of age showed that free drug AUC increased by 40% and Cmax increased by 60% as compared with estimates of the same parameters in young subjects (those younger than 35 years of age; see DOSAGE AND ADMINISTRATION).

Also in the elderly, the ratio of intrinsic clearance/availability decreased by 35% and plasma half-life was prolonged by 26%. This reduction is thought to be due to a decrease in hepatic extraction associated with aging.

###  Renally Impaired

Studies of the effects of renal-function impairment have been small. They indicate a decrease in clearance in patients with impaired renal function. In 23 patients with renal impairment, free ketoprofen peak concentration was not significantly elevated, but free ketoprofen clearance was reduced from 15 L/kg/h for normal subjects to 7 L/kg/h in patients with mildly impaired renal function, and to 4 L/kg/h in patients with moderately to severely impaired renal function. The elimination t1/2 was prolonged from 1.6 hours in normal subjects to approximately 3 hours in patients with mild renal impairment, and to approximately 5 to 9 hours in patients with moderately to severely impaired renal function.

###  Hepatically Impaired

For patients with alcoholic cirrhosis, no significant changes in the kinetic disposition of immediate-release ketoprofen capsules were observed relative to age-matched normal subjects: the plasma clearance of drug was 0.07 L/kg/h in 26 hepatically impaired patients. The elimination half-life was comparable to that observed for normal subjects. However, the unbound (biologically active) fraction was approximately doubled, probably due to hypoalbuminemia and high variability which was observed in the pharmacokinetics for cirrhotic patients. Therefore, these patients should be carefully monitored and daily doses of ketoprofen kept at the minimum providing the desired therapeutic effect.
FIELD: cosmetology. SUBSTANCE: invention deals with conditioning and washing cosmetic composition for keratin fibers. Said composition contains in aqueous medium: (A) at least one nonvolatile vegetable oil, (B) at least one anionic surface-active substance of sulfate type, and (C) at least one nonionic surface-active substance of alkylpolyglycoside type. Ratio of B to C is less or equal to 2. Proposed method also deals with washing and conditioning of keratin materials, particularly, hair using said composition. The composition gives hair softness and shine. EFFECT: sufficient foaming; better conditioning properties. 21 cl, 5 tbl, 5 ex
FIELD: medicine. SUBSTANCE: method involves administering hyperbaric oxygenation sessions by applying 1.5 Atm large pressure for 60 min. 400 ml of hemodesis is injected as intravenous drop infusion in the first day after morning hyperbaric oxygenation session. Oxygen is administered at the second day by making lumbar puncture into subarachnoid space of spinal cord and brain in the amount of 60 ml. The treatment is continued like one applied in the first day in the third and following days. The total treatment course is 10 days long. EFFECT: enhanced effectiveness of treatment.
Following screening to determine eligibility (normal medical history, physical examination including vital signs, laboratory findings, negative test for active H. pylori infection, and a negative pregnancy test if applicable) and subsequent enrolment, patients will have a baseline 24-hour intragastric pH recording. Patients will receive either oral rabeprazole 20mg or intravenous pantoprazole 40mg daily for 3 consecutive days. For blinding purposes, patients will also receive either a placebo oral tablet or placebo intravenous solution ("double-dummy" design). A 24-hour intragastric pH recording will be completed on Day 1 and Day 3 of the drug administration period. This will be followed by a 14-day washout period before the second 3-day drug administration period during which the patient will receive the crossover drug regimen, and will again have 24-hour intragastric pH recordings completed on the first and third days of this second drug administration period.Thirty-seven patients with a negative test for active H. pylori infection test will be randomised into the study. The primary hypothesis is that oral rabeprazole produces equivalent acid suppression to intravenous pantoprazole as indicated by the time during which intragastric pH is greater than 4 on Day 1 of drug administration. Eligible patients will be randomly assigned to 1 of the 2 treatment groups and will first receive either oral rabeprazole 20mg plus placebo intravenous solution or intravenous pantoprazole 40mg plus a placebo oral tablet daily for 3 consecutive days. After a 14-day washout, patients will receive the crossover drug regimen.

Rabeprazole: supplied as 20mg tablets (and matching placebo tablets). Pantoprazole: supplied as 12-mL vials of lyophilized powder containing pantoprazole 40mg (pantoprazole
This is an open, prospective, dose-escalating study, designed to elucidate the pharmacokinetics, pharmacodynamics, safety, and tolerability of pentoxifylline in children of the ages greater than/equal to 9 months and less than/equal to 96 months with cerebral malaria. The study is designed to evaluate pentoxifylline as adjunct therapy in severe pediatric malaria by evaluating its toxicity and associated adverse events, and by establishing both an acceptable dose and the associated pharmacokinetic profile. The pharmacodynamic effects of four different dose levels (10, 20, 30, and 40 mg/kg/24 hours) will be accessed on the following biological, immunological, and parasitological parameters: cerebral blood flow velocity, tumor necrosis factor concentration, rosetting, coma resolution time, parasite clearance time, and fever clearance time. Due to the variability observed in the biological, immunological, and parasitological parameters under scrutiny, a control group of ten patients will be intercalated in the study (4 patients prior to enrollment of the first pentoxifylline recipient, 2 patients in-between each of the 3 dose escalations). As there is no information about the relationship of treatment duration to biological, immunological, and parasitological effects, treatment will continue for 72 hours, by which time peripheral parasitemia will have cleared in the majority of patients. The selection of the pentoxifylline dosage regimen for the larger, multi center Phase II and Phase III studies will be made on the basis of the maximum tolerated dose (based on clinical and laboratory observations) which minimizes the dose-related side-effects and adverse events (based on pharmacokinetics) while permitting maximum biological, immunological, and/or parasitological effects (pharmacodynamics).
PURPOSE:A safe anemia preventing agent, obtained by incorporating l-tryptophan or a derivative thereof as an active constituent in an animal tissue extract, etc., and capable of very remarkably preventing iron deficiency anemia. CONSTITUTION:An anemia preventing agent, obtained by incorporating l-tryptophan or a derivative thereof, e.g. n-acetyl-l-tryptophan or 5-hydroxytryptophan, in a substance selected from an animal tissue extract, pulverized animal tissue or enzymic decomposition product. A mammal, e.g. cattle or pig, bird, fish or shellfish, etc. may be used as the animal, and the liver or blood is preferably used in the case of particularly a large animal. A pharmaceutical containing the tissue extract, etc. and l-tryptophan at 1:0.1-20 compounding ratio has particularly good anemia preventing effect.
FIELD: medicine. SUBSTANCE: the suggested method deals with manufacturing curative-nutritive products out of animal blood. The method includes blood sampling in Siberian stags and sika deer during cutting velvet anthlers; plasma, blood elements and crude blood protein keeping; mixing it with sweet filler, alcohol, fruit essence, ascorbic acid followed by pasteurization of the mixture. Moreover, additionally, one should carry out triple blood sampling during the period from May to November in stag beetles not participating in heat and single blood sampling in females after heat. Moreover, plasma, blood elements and crude blood protein should be kept due to the method of blood stabilization. As for pasteurization, it is carried out with high-frequency currents, and as sweet filler one should use glucose solution prepared at the following ratio: 1 weight portion to 2 portions of dry glucose. The present method enables to considerably increase production of pantohematogen and improve its quality. EFFECT: higher efficiency of manufacturing. 1 cl, 6 tbl
A computerized medical diagnostic system uses a training dataset that is updated based on radiologist feedback. A radiologist incorporates a 3D cursor into his checklist approach to a cross-sectional imaging study. A CAD and/or AI algorithm is performed on the sub-volumes. Findings identified by an AI / CAD algorithm can be presented to the radiologist via unobstructed viewing through segmentation and filtering. A process for adjudicating disagreements between the AI and the radiologist using "virtual buckets" is used. Radiologists perform image markup, label the images with finding terminology, diagnoses and certainty levels and then add sub-volumes each bucket thereby expanding the training dataset for subsequent AI algorithms.
Patients undergoing treatment with adriamycin-containing chemotherapy frequently develop significant anemia. Agents that can increase the amount of hemoglobin in cancer patients undergoing treatment with non-platinum-containing cyclic chemotherapy may improve the patients' reduced physical strength and reduced stamina resulting from anemia, improve the patients' ability to continue chemotherapy, and improve the patients' overall qualify of life. Epoetin alfa is a genetically engineered form of a natural hormone, erythropoietin, that is used to treat anemia by stimulating red blood cell production. This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study. The study evaluates the safety and effectiveness of epoetin alfa in treating patients who develop persistent anemia as a result of treatment with aggressive non-platinum-containing cyclic chemotherapy for any cancer type (except rapid and severe onset of leukemias and malignancies of the bone marrow and spleen). The study consists of a screening period when patients' eligibility is determined, a 12-week double-blind treatment period when patients receive 3 injections each week with either epoetin alfa or placebo, and an optional open-label treatment period when patients who choose to continue will receive 3 injections of epoetin alfa per week during any remaining cycles of their chemotherapy. Eligible patients will be randomly assigned to one of two treatment groups: one group receiving epoetin alfa 150 units/kilogram and the other group receiving a comparable volume of placebo. Study drug is administered by injection beneath the skin 3 times weekly for 12 weeks. The dose of study medication may be increased or decreased at the discretion of the physician, based on the results of blood tests. Depending on the patient's chemotherapy cycle, he or she will return to the study site every 3 or 4 weeks for administration of study medication. Safety evaluations (laboratory tests, vital sign measurements, reporting of adverse events, physical examination, and electrocardiogram) are performed throughout the study. The primary measures of effectiveness of the study drug will be determined by the number of transfusions patients require and by changes in blood test results for hemoglobin, hematocrit, and reticulocytes (immature red blood cells) from before the start of the study to the end of the study. The study hypothesis is that epoetin alfa will, more effectively than placebo, stimulate adequate production of red blood cells to increase the hemoglobin level in cancer patients who are anemic as a result of undergoing treatment with aggressive non-platinum-containing cyclic chemotherapy. Double-blind: Epoetin alfa 150 units/kilogram (U/kg) or matching volume placebo injected beneath the skin 3 times weekly for 12 weeks. Open-label: Epoetin alfa at the dose received at the end of the double-blind study injected beneath the skin 3 times weekly for any remaining cycles of chemotherapy.
Compressed tablets containing salts of cinchona alkaloids are rendered rapidly soluble in water by incorporation of sarcosin anhydride or a homologue thereof with the salt before compression into tablets.  According to examples sarcosin anhydride may be added to quinine hydrochloride, to quinine bishydrochloride, or to mixtures of quinine hydrochloride with quinine base or with a mixture of quinidine base, cinchonine base and hydroquinine base, or tablets may be prepared from the complex compound referred to in the parent Specification and obtained by dissolving 1 mol. of quinine hydrochloride and 3 mols. of sarcosine anhydride in benzene and evaporating the solvent.  Sarcosin anhydride may be replaced by 1.4-diethyl-2.5-diketopiperazine or 3 methyl-2.5-diketopiperazine.ALSO:Compressed tablets containing salts of cinchona alkaloids are rendered rapidly soluble in water by incorporating sarcosin anhydride or a homologue thereof with the salt before compression into tablet form.  According to examples sarcosin anhydride may be added to quinine hydrochloride, to a mixture of quinine hydrochloride and quinine base, to a mixture of quinine hydrochloride, quinidine base, cinchonine base and hydroquinine base, or to quinine bishydrochloride, or tablets may be prepared from the complex compound referred to in the parent Specification and obtained by dissolving 1 mol. of quinine hydrochloride and 3 mols. of sarcosine anhydride in benzene and evaporating the solvent.  Sarcosin anhydride may be replaced by 1,4-diethyl-2,5-diketopiperazine, or by 3 methyl-2,5-diketopiperazine.  Other ingredients such as amylose, milk sugar, boric acid, or sorbitol or mixtures thereof may be added to the tablets.
During anesthesia induction of patients receiving inhalation anesthesia, 60 mg 2% lidocaine, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide and 1 mcg/kg fentanyl will be used. Desflurane will be used with a minimum alveolar concentration of 1 and for additional intraoperative sedation. remifentanil will be given between 0.05 and 0.2mcg/kg/min according to the patient's needs.
The transmission dynamics and presenting symptoms of intestinal spirochaetosis (Brachyspira pilosicoli, Brachyspira aalborgi) are poorly understood but is seen more frequently in men who have sex with men (MSM) where sexual transmission may occur. We aimed to systemically review the literature to define the factors and presenting symptoms associated with intestinal spirochaetosis in MSM. We systematically searched three bibliographical databases (MEDLINE, EMBASE and Scopus) for manuscripts written in English up to November 2022. The primary author conducted an initial screen and three authors conducted independent reviews to determine the final eligible manuscripts. We only included manuscripts where there were specific data on factors and presenting symptoms associated with intestinal spirochaetosis in MSM. Fifteen manuscripts published between 1981 and 2022 met the inclusion criteria that included 188 MSM. Sexually transmitted intestinal spirochaetosis in MSM was associated with-living with HIV (including having a low CD4 count <200 mm3), having a concomitant sexually transmitted infection, a history of a sexually transmitted infection, co-infection with intestinal parasites; and sexual behaviour including oro-anal sexual contact, oro-genital contact, fisting, condom-less anal sex, receptive anal sex, multiple non-regular sexual partners and increased number of lifetime sexual partners. The presenting symptoms of MSM with intestinal spirochaetosis were diarrhoea, abdominal pain, constitutional symptoms and proctitis, including rectal pain, rectal bleeding rectal discharge, flatulence and tenesmus. We have highlighted some biological and behavioural factors and presenting symptoms associated with intestinal spirochaetosis in MSM which provide insight for clinicians, guidelines and future public health control strategies.
Helicobacter pylori (Hp) is the main trigger of chronic gastric atrophy and the main leading cause of gastric cancer. Hp infects the normal gastric mucosa and can lead to chronic inflammation, glandular atrophy, intestinal metaplasia, dysplasia and finally adenocarcinoma. Chronic inflammation and gastric atrophy associated with Hp infection appear initially in the distal part of the stomach (the antrum) before progressing to the proximal part (the corpus-fundus). In recent years, endoscopic developments have allowed for the characterization of various gastric conditions including the normal mucosa (pyloric/fundic gland pattern and regular arrangement of collecting venules), Hp-related gastritis (Kyoto classification), glandular atrophy (Kimura-Takemoto classification), intestinal metaplasia (Endoscopic Grading of Gastric Intestinal Metaplasia), and dysplasia/adenocarcinoma (Vessel plus Surface classification). Despite being independent classifications, all these scales can be integrated into a single model: the endoscopic model for gastric carcinogenesis. This model would assist endoscopists in comprehending the process of gastric carcinogenesis and conducting a systematic examination during gastroscopy. Having this model in mind would enable endoscopists to promptly recognize the implications of Hp infection and the potential patient's risk of developing gastric cancer.
A system and a method for cloud medical image analysis are provided. The system for cloud medical image analysis has a cloud medical analysis platform and an electronic device. The electronic device obtains a medical image. The electronic device quantifies the medical image to obtain a first feature value. The electronic device sends the first feature value to the cloud medical analysis platform. The cloud medical analysis platform inputs the first feature value into an analysis module to obtain an analysis result, wherein the analysis module uses a self-learning module and the analysis module is trained via a plurality of training images. The cloud medical analysis platform sends the analysis result to the electronic device.
Autism is a serious childhood disorder that can significantly impair functioning and development. Educational and psychosocial programs are standard treatments for autistic children, but drug therapy is often needed as well. Haloperidol is the drug most commonly prescribed for symptoms of autism. However, long-term administration of haloperidol has been associated with adverse effects such as blurred vision, constipation, and nausea. The investigation of alternative drug treatments is necessary. This study will determine whether the antipsychotic drug olanzapine may be a safe and effective alternative to haloperidol for treating symptoms of autism in children.

This study will last 36 weeks and will comprise 2 phases. In Phase I, participants will be randomly assigned to receive either olanzapine or placebo for 12 weeks. Participants who do not respond to treatment will complete their participation in the study. Participants who respond to their assigned Phase I treatment will continue onto Phase II. All Phase II participants will receive olanzapine daily for 6 months. Self-report scales and checklists will be used to assess participants after each phase; these measures will be completed by participants and their parents.